A
72.92
0.00 (-0.01%)
| Previous Close | 72.92 |
| Open | 73.00 |
| Volume | 1,064,021 |
| Avg. Volume (3M) | 2,208,078 |
| Market Cap | 11,263,826,944 |
| Price / Sales | 459.10 |
| Price / Book | 5.97 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Operating Margin (TTM) | -8,360.90% |
| Diluted EPS (TTM) | -3.00 |
| Quarterly Revenue Growth (YOY) | -55.60% |
| Total Debt/Equity (MRQ) | 0.45% |
| Current Ratio (MRQ) | 16.91 |
| Operating Cash Flow (TTM) | -355.32 M |
| Levered Free Cash Flow (TTM) | -245.73 M |
| Return on Assets (TTM) | -22.47% |
| Return on Equity (TTM) | -34.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Avidity Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.4
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -5.0 |
| Technical Oscillators | 2.0 |
| Average | -0.38 |
|
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.17% |
| % Held by Institutions | 112.41% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fmr Llc | 30 Sep 2025 | 21,585,984 |
| Janus Henderson Group Plc | 30 Sep 2025 | 14,522,915 |
| Rtw Investments, Lp | 30 Sep 2025 | 11,372,829 |
| Wellington Management Group Llp | 30 Sep 2025 | 10,065,187 |
| Price T Rowe Associates Inc /Md/ | 30 Sep 2025 | 9,787,417 |
| Ra Capital Management, L.P. | 30 Sep 2025 | 8,641,031 |
| Avoro Capital Advisors Llc | 30 Sep 2025 | 7,645,000 |
| Norges Bank | 31 Dec 2025 | 3,046,388 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 2,796,760 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | Avidity Biosciences Announces Expected Record Date for Spin-Off |
| 19 Nov 2025 | Announcement | Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |